Integrated Nanotherapeutics Inc.

Integrated Nanotherapeutics Inc. (INT) is a biopharmaceutical company (Vancouver, Canada) that is developing a new class of therapeutics, “antigen-specific immune tolerance” using their proprietary multi-cargo lipid nanoparticles (LNPs) platform to deliver mRNA of one or multiple auto-antigens, along with an immune modulator small molecule to train the immune system not to attack self-antigen and to treat autoimmune diseases. In addition, INT is partnering with biotech and pharma companies to develop novel LNP-based therapeutics for their cargo of interest in various indications, including cancers and infectious diseases.